Chronic Venous Occlusions Treatment Market Size & Growth Forecast 2027–2036, By Segments (Product, End Use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Chronic Venous Occlusions Treatment Market size was worth USD 7.57 billion in 2026 and is expected to grow at a 5.08% CAGR between 2027 and 2036, surpassing USD 12.43 billion by 2036. The industry revenue for 2027 is calculated at USD 7.89 billion.
Get more details on this report
Request Free Sample ReportChronic Venous Occlusions Treatment Market Intelligence Snapshot
Regional Market Dynamics
- North America held 42.51% of the market in 2026, supported by advanced vascular care infrastructure, specialized interventional services, increasing awareness of venous disorders, and investment in minimally invasive treatments.
- Asia Pacific is growing fastest as healthcare modernization, rising awareness of vascular diseases, aging populations, and improved access to specialist services increase demand for advanced diagnosis and minimally invasive interventions.
Segment Momentum
- Devices accounted for 54.49% of the market in 2026 and are also the fastest-growing product segment. Advances in catheter-based technologies and vessel-recanalization techniques support minimally invasive treatment and restoration of venous blood flow.
- Hospitals held a 62.5% market share in 2026 and are also the fastest-growing end-use segment. Their specialized vascular expertise, advanced imaging, and interventional infrastructure support complex procedures, patient monitoring, and follow-up care.
Market Expansion Drivers
- Increasing prevalence of chronic venous diseases and aging population.
- Advancements in minimally invasive endovascular treatment techniques.
- Improved reimbursement frameworks for venous interventions.
Leading Market Participants
- Leading companies in the chronic venous occlusions treatment market include Medtronic (Ireland), Boston Scientific (United States), BD (United States), Cook Medical (United States), Abbott (United States), Terumo (Japan), Cardinal Health (United States), AngioDynamics (United States), B. Braun (Germany), Merit Medical (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 7.57 billion
- 2027 Estimated Market Size: USD 7.89 billion
- Projected Market Size: USD 12.43 billion by 2036
- Growth Forecast: 5.08% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Product (Devices) | End Use (Hospitals) | Application (Varicose Veins)
- Emerging Opportunity Segment: Product (Devices) | End Use (Hospitals) | Application (Varicose Veins)
Market Growth Drivers and Industry Trends
Increasing Prevalence of Chronic Venous Diseases and Aging Population
The increasing prevalence of chronic venous diseases and the aging population are driving demand for treatments targeting chronic venous occlusions. Age-related changes in vascular health, reduced mobility, and the growing occurrence of conditions associated with impaired venous circulation can contribute to persistent symptoms and complications requiring clinical intervention. Patients with chronic venous occlusions may experience pain, swelling, and reduced quality of life, increasing the need for effective diagnostic and therapeutic approaches. As the population of older adults expands and awareness of venous disease management improves, the demand for specialized treatment options is supporting market growth.
Advancements in Minimally Invasive Endovascular Treatment Techniques
Advancements in minimally invasive endovascular treatment techniques are expanding therapeutic options for patients with chronic venous occlusions while reducing the need for more invasive surgical approaches. Improvements in catheter-based crossing techniques, lesion preparation, recanalization methods, and intravascular imaging are enabling clinicians to manage complex venous blockages with greater procedural control. These approaches can facilitate restoration of venous flow while potentially reducing recovery requirements compared with conventional surgical interventions. As physicians increasingly adopt less invasive techniques for challenging vascular conditions, technological progress in endovascular treatment is strengthening demand for specialized chronic venous occlusion therapies.
Improved Reimbursement Frameworks for Venous Interventions
Improved reimbursement frameworks for venous interventions are supporting market development by increasing access to clinically appropriate treatment options and encouraging healthcare providers to perform specialized procedures. Favorable reimbursement coverage can reduce financial barriers for patients while providing healthcare facilities with greater support for the resources, equipment, and expertise required for endovascular interventions. As recognition of the clinical burden associated with untreated or inadequately managed venous disease increases, reimbursement policies are evolving to support broader access to vascular treatments. This improving healthcare financing environment is contributing to greater utilization of chronic venous occlusion interventions.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing prevalence of chronic venous diseases and aging population | 1.4% | Short term (≤ 2 yrs) | Europe; North America (Asia Pacific) | Medium | Fast |
| Advancements in minimally invasive endovascular treatment techniques | 1.2% | Medium term (2–5 yrs) | North America; Europe (Asia Pacific) | Medium | Moderate |
| Improved reimbursement frameworks for venous interventions | 0.9% | Long term (5+ yrs) | Europe; North America (Asia Pacific) | High | Slow |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America accounted for a 42.51% share of the chronic venous occlusions treatment market in 2026, led by advanced vascular care infrastructure, increasing awareness of venous disorders, and widespread access to specialized diagnostic and interventional treatment services. Healthcare providers across the region are increasingly focusing on early diagnosis and effective management of chronic venous conditions to reduce complications and improve patient quality of life. Advances in minimally invasive vascular interventions are supporting demand for specialized treatment approaches that can restore venous blood flow and address complex occlusions with reduced procedural burden. The growing prevalence of risk factors associated with vascular disorders is also increasing the need for diagnosis, monitoring, and long-term treatment. In addition, established healthcare systems, availability of specialized vascular specialists, and continued investment in interventional technologies are supporting adoption of advanced treatment solutions across hospitals and specialized vascular centers.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to witness the fastest growth in the chronic venous occlusions treatment market, influenced by expanding healthcare infrastructure, increasing awareness of vascular diseases, and improving access to specialized diagnostic and interventional care. Rising healthcare expenditure and modernization of hospitals are enabling more patients to receive advanced treatment for chronic vascular conditions. Increasing prevalence of lifestyle-related risk factors and an aging population are also contributing to greater demand for vascular diagnosis and treatment services. Healthcare systems across the region are increasingly adopting minimally invasive procedures as awareness of their clinical and recovery benefits grows, creating opportunities for advanced technologies used to manage complex venous occlusions. Furthermore, expanding specialist networks, improved diagnostic capabilities, and greater availability of interventional vascular services are supporting the adoption of modern chronic venous occlusion treatment approaches across emerging and developed healthcare markets in Asia Pacific.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Complex Venous InterventionThe U.S. chronic venous occlusions treatment market supports advanced endovascular approaches for patients requiring complex venous revascularization. Clinical adoption priorities include procedural effectiveness, specialized devices, physician familiarity with intervention techniques, and technologies that facilitate treatment of difficult occlusive lesions.
Germany 🇩🇪
Minimally Invasive TreatmentGermany's market for chronic venous occlusions treatment emphasizes minimally invasive approaches that can address complex vascular disease while supporting controlled clinical workflows. Device selection is influenced by procedural reliability, lesion-crossing capabilities, treatment precision, and integration into specialist vascular care.
Japan 🇯🇵
Precision Vascular TherapyJapan's chronic venous occlusions treatment market favors precise, carefully controlled interventions for complex venous disease. Commercial priorities include catheter performance, navigability, procedural safety, and technologies that help specialists manage challenging occlusions while limiting treatment burden.
South Korea 🇰🇷
Endovascular Technique AdoptionSouth Korea's chronic venous occlusions treatment market is supported by continued use of catheter-based vascular interventions. Hospitals and specialists can prioritize devices offering improved lesion access, controlled treatment delivery, procedural efficiency, and compatibility with established interventional workflows.
France 🇫🇷
Specialist Vascular CareFrance's market is shaped by specialist management of chronic venous disease and the use of minimally invasive treatment pathways. Commercial opportunities center on dependable intervention technologies, procedural precision, patient recovery considerations, and equipment suited to complex occlusion management.
Italy 🇮🇹
Endovascular Care AccessItaly's chronic venous occlusions treatment market is supported by specialist vascular services using catheter-based approaches for difficult venous disease. Treatment technologies that improve procedural control, access challenging lesions, and simplify intervention can strengthen adoption across appropriate clinical settings.
Chronic Venous Occlusions Treatment Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Devices (Largest & Fastest-Growing Segment)
The devices segment accounted for a market share of 54.49% in 2026 and is also expected to grow at the fastest pace, reflecting the central role of interventional devices in restoring venous blood flow and managing chronic venous occlusions. Treatment devices can support procedures designed to cross obstructed vessels, restore patency, and improve circulation, making them fundamental to minimally invasive approaches for patients with persistent venous blockages. Advances in catheter-based technologies, guidewire design, and vessel-recanalization techniques are expanding the ability of clinicians to address complex occlusions while limiting the need for more invasive interventions. Growing preference for minimally invasive treatment, alongside increasing recognition of the clinical burden associated with chronic venous disease, is supporting demand for specialized devices. Continued development of technologies that improve procedural control, navigation, and vessel restoration is further strengthening the role of devices in the treatment landscape.
End Use Segment Analysis: Hospitals (Largest & Fastest-Growing Segment)
The hospitals end-use segment accounted for a market share of 62.5% in 2026 and is also expected to experience the fastest growth, supported by the availability of specialized vascular expertise, advanced imaging, and interventional infrastructure required to manage complex venous occlusions. Hospitals provide an integrated clinical environment where patients can undergo diagnosis, minimally invasive procedures, post-treatment monitoring, and follow-up care in the same healthcare setting. Their ability to accommodate complex cases and provide multidisciplinary vascular services makes hospitals particularly important for patients requiring advanced treatment approaches. Increasing investment in interventional facilities and improvements in catheter-based treatment capabilities are further supporting hospital-based management of chronic venous occlusions. As awareness of venous disease increases and treatment pathways increasingly emphasize minimally invasive interventions, hospitals are expected to remain a major setting for advanced venous occlusion treatment.
Application Segment Analysis: Varicose Veins (Largest & Fastest-Growing Segment)
The varicose veins application segment accounted for a market share of 51.62% in 2026 and is also expected to grow at the fastest pace, reflecting the substantial clinical burden associated with chronic venous disease and the demand for effective management of impaired venous circulation. Varicose veins develop when weakened or dysfunctional veins allow blood to pool, resulting in enlarged and visibly prominent veins that can be accompanied by discomfort, swelling, and other symptoms. Treatment approaches increasingly emphasize minimally invasive techniques that can improve venous flow while reducing procedural burden and recovery time. Growing awareness of venous health, greater attention to symptoms that affect mobility and quality of life, and improvements in interventional treatment technologies are supporting demand in this application. The increasing availability of specialized procedures and improved clinical management pathways is further contributing to the expansion of treatment opportunities for patients with varicose vein-related venous disorders.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Devices, Drugs | Devices | Devices |
| End Use | Hospitals, Ambulatory Surgical Centers, Others | Hospitals | Hospitals |
| Application | Varicose Veins, Edema, Deep Vein Thrombosis, Venous Stasis Ulcers, Others | Varicose Veins | Varicose Veins |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
Clinical differentiation hinges on proving sustained long-term vessel patency and procedural recanalization rather than relying solely on immediate technical success. Because extensive and anatomically complex occlusion sites present distinct challenges, device success relies heavily on catheter flexibility, navigability, and deliverability under real clinical conditions. Moreover, balancing flow restoration with lower post-procedural complication rates—such as thrombosis or bleeding—is vital. Ultimately, stenting and thrombus removal techniques must be tailored to varied clot burdens and anatomy, as initial flow restoration does not inherently guarantee durable, long-term patient benefit.
Top players in the chronic venous occlusions treatment market:
- Medtronic (Ireland)
- Boston Scientific (United States)
- BD (United States)
- Cook Medical (United States)
- Abbott (United States)
- Terumo (Japan)
- Cardinal Health (United States)
- AngioDynamics (United States)
- B. Braun (Germany)
- Merit Medical (United States)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Medtronic (Ireland) | |||||||
| Boston Scientific (United States) | |||||||
| BD (United States) | |||||||
| Cook Medical (United States) | |||||||
| Abbott (United States) | |||||||
| Terumo (Japan) | |||||||
| Cardinal Health (United States) | |||||||
| AngioDynamics (United States) | |||||||
| B. Braun (Germany) | |||||||
| Merit Medical (United States) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| AngioDynamics Inc. | April 2024 | AngioDynamics received FDA clearance for its AlphaVac F1885 System for the treatment of pulmonary embolism. The regulatory milestone expands the system's clinical applications to enable the non-surgical removal of thrombi or emboli from the venous vasculature, strengthening the company's interventional cardiology and venous therapy portfolio. |
| THERACLION | May 2022 | THERACLION launched SONOVEIN HD, combining advanced ultrasound imaging technology from SuperSonic Imagine with its extracorporeal therapeutic ultrasound solution. The launch introduces a high-definition robotic platform to commercial non-invasive venous defect and vascular treatment markets. |
| I-VASC | April 2022 | Italian medical device innovator I-VASC secured EUR 1.8 million in Series A funding to support the commercialization of its CE-marked VELEX device. Designed for Empty Vein Ablation, the system targets chronic venous insufficiency and varicose veins, accelerating commercial scaling in minimally invasive vascular care. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Chronic Venous Occlusions Treatment Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Treatment Line | Initial treatment, Repeat or reintervention treatment, Long-term maintenance treatment |
| Lesion Location | Iliac veins, Femoral or popliteal veins, Tibial or calf veins, Multiple venous segments |
| Treatment Approach | Endovascular intervention, Surgical intervention, Pharmacological management, Combination therapy |
Chronic Venous Occlusions Treatment Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Treatment Pathway & Referral Dynamics |
|
| Clinical Evidence & Guideline Influence |
|
| Patient Access & Care Gaps |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
How big is the chronic venous occlusions treatment market?
How is the chronic venous occlusions treatment industry size expected to evolve during the forecast period?
How are minimally invasive endovascular advances influencing treatment adoption for chronic venous occlusions?
How are reimbursement improvements influencing access to chronic venous occlusion treatments?
Why do devices dominate the chronic venous occlusions treatment market?
Why are hospitals the leading and fastest-growing end-use segment in chronic venous occlusions treatment?
Why does North America lead the chronic venous occlusions treatment market?
How is Asia Pacific strengthening its position in the chronic venous occlusions treatment market?
What are the prominent companies operating in the chronic venous occlusions treatment landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook